risks of taking glp 1 Key Takeaways Patients GLP-1 receptor agonists for weight loss had a 41% lower risk obesity-associated cancers compared with patients prescribed diet or exercise. Patients taking tirzepatide had substantially greater cancer GLP-1 receptor agonists are increasingly

The literature identifies hypoglycemia as the most significant documented risk, driven by IGF-1 LR3s effect on cellular glucose uptake, alongside receptor desensitization with prolonged exposure and contraindications for individuals with a history of malignancy

However, the absence of documented interactions does not automatically mean the combination is appropriate for everyone

Physical activity Safe, pregnancy-friendly exercises like walking or prenatal yoga can help maintain health

Its tempting because you might still lose weight, but it can result in developing bad habits that are hard to kick once you reach your healthy weight and look to wean off the drug